Jennifer Humes
Net worth: 4 M $ as of 2026-08-30
Net worth: 4 M $ as of 2026-08-30
Jennifer Humes is Chief Accounting Officer at Roivant Sciences Ltd. and Roivant Sciences, Inc., starting in 2025.
Ms. Humes worked at JPMorgan Chase & Co. from 2016 to 2024, serving as Controller-Global Investment Banking in 2024.
Ms. Humes completed undergraduate education at the University of St. Thomas.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-09-19 | 106,419 ( 0.01% ) | 4 M $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| ROIVANT SCIENCES LTD. | Comptroller/Controller/Auditor | 2025-02-19 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Comptroller/Controller/Auditor | 2025-02-19 |
| Companies | Position | End |
|---|---|---|
| JPMORGAN CHASE & CO. | Corporate Officer/Principal | 2024-11-30 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
JPMorgan Chase & Co.
JPMorgan Chase & Co. Major BanksFinance Provides banking, asset management, investment banking, credit card and mortgage services | Finance |
Roivant Sciences Ltd.
Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
University of St. Thomas
University of St. Thomas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Select your edition
All financial news and data tailored to specific country editions